menu ☰
menu ˟

Thyroid hormone receptor agonist improves liver fat, lipoproteins in NASH

07 Dec 2017
Madrigal Pharmaceuticals announced positive interim results from a phase 2 clinical trial of MGL-3196 for reducing liver fat in patients with nonalcoholic steatohepatitis, according to a press release and company presentation.Paul A. Friedman Rebecca...

Click here to view the full article which appeared in

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.